ARTICLE | Clinical News
TiGenix to discontinue cardiovascular pipeline
December 22, 2017 8:23 PM UTC
TiGenix N.V. (Euronext:TIG; NASDAQ:TIG) said it will discontinue development of its allogeneic cardiovascular stem cell program, including AlloCSC-01, to focus on candidates derived from its expanded adipose-derived stem cell (eASC) platform, including Alofisel darvadstrocel (Cx601) and Cx611.
This month, CHMP backed approval of Alofisel to treat complex perianal fistulas in patients with Crohn’s disease (see BioCentury, Dec. 21). ...